• MannKind Corp MNKD.OQ reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of four analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from 2 cents to 4 cents per share.

• Revenue fell 61.5% to $19.73 million from a year ago; analysts expected $74.50 million.

• MannKind Corp's reported EPS for the quarter was 4 cents​.

• The company reported quarterly net income of $11.55 million.

• MannKind Corp shares had risen by 17.5% this quarter and gained 103.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for MannKind Corp is $9.00

This summary was machine generated from LSEG data November 8 at 05:24 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)